These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15363822)

  • 1. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
    Jamerson KA; Bakris GL; Wun CC; Dahlöf B; Lefkowitz M; Manfreda S; Pitt B; Velazquez EJ; Weber MA
    Am J Hypertens; 2004 Sep; 17(9):793-801. PubMed ID: 15363822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
    Weber MA; Bakris GL; Dahlöf B; Pitt B; Velazquez E; Gupte J; Lefkowitz M; Hester A; Shi V; Weir M; Kjeldsen S; Massie B; Nesbitt S; Ofili E; Jamerson K
    Blood Press; 2007; 16(1):13-9. PubMed ID: 17453747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design.
    Ogihara T; Matsuzaki M; Matsuoka H; Shimamoto K; Shimada K; Rakugi H; Umemoto S; Kamiya A; Suzuki N; Kumagai H; Ohashi Y; Takishita S; Abe K; Saruta T;
    Hypertens Res; 2005 Apr; 28(4):331-8. PubMed ID: 16138563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
    Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
    J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.
    J Hypertens; 1998 Feb; 16(2):127-37. PubMed ID: 9535138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective.
    Kjeldsen SE; Weber M; Oparil S; Jamerson KA
    Blood Press; 2008; 17(5-6):260-9. PubMed ID: 19061055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
    Ferguson JM; Minas J; Siapantas S; Komesaroff PA; Sudhir K
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):590-5. PubMed ID: 18520951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.